These findings suggest that tirzepatide preserves the cardioprotective benefits of GLP-1 receptor agonists while offering additional metabolic and renal advantages, reinforcing its potential as a preferred therapy for patients with T2DM and high cardiovascular risk. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.